Vertex Pharmaceuticals Incorporated Stock

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-16 pm EDT 5-day change 1st Jan Change
394.2 USD -0.80% Intraday chart for Vertex Pharmaceuticals Incorporated -2.55% -3.13%
Sales 2024 * 10.72B Sales 2025 * 11.75B Capitalization 103B
Net income 2024 * 3.87B Net income 2025 * 4.47B EV / Sales 2024 * 7.98 x
Net cash position 2024 * 17.11B Net cash position 2025 * 21.54B EV / Sales 2025 * 6.91 x
P/E ratio 2024 *
26.6 x
P/E ratio 2025 *
23.1 x
Employees 5,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.89%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Vertex Pharmaceuticals Incorporated

1 day+0.20%
1 week-1.70%
Current month-4.94%
1 month-2.53%
3 months-8.32%
6 months+7.11%
Current year-2.34%
More quotes
1 week
393.76
Extreme 393.76
404.69
1 month
393.76
Extreme 393.76
421.45
Current year
393.76
Extreme 393.76
448.40
1 year
316.43
Extreme 316.43
448.40
3 years
176.36
Extreme 176.36
448.40
5 years
163.68
Extreme 163.681
448.40
10 years
62.41
Extreme 62.405
448.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 17-01-31
Chairman 68 09-07-07
Director of Finance/CFO 55 19-04-09
Members of the board TitleAgeSince
Director/Board Member 68 17-06-07
Chairman 68 09-07-07
Director/Board Member 64 97-12-31
More insiders
Date Price Change Volume
24-04-16 394.2 -0.80% 695,469
24-04-15 397.4 +0.20% 1,373,702
24-04-12 396.6 -0.92% 1,200,426
24-04-11 400.2 +0.67% 1,060,331
24-04-10 397.6 -1.71% 1,026,680

Delayed Quote Nasdaq, April 15, 2024 at 04:00 pm EDT

More quotes
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
397.4 USD
Average target price
461.3 USD
Spread / Average Target
+16.08%
Consensus